10-K: Lifeloc Technologies Reports Wider Loss Amid SpinDetect Push

Lifeloc Technologies, Inc. reported a significantly increased net loss for fiscal year 2025, driven by strategic investments in its SpinDetect platform and higher interest expenses, despite a modest revenue increase.

Summary

• Total revenues for 2025 increased by 6% to $9,026,938, up from $8,538,145 in 2024, primarily due to new customer acquisitions and expansion in existing accounts.
• Net loss for 2025 significantly widened to $2,470,399, compared to a net loss of $1,052,948 in 2024, largely due to an increase in the deferred tax asset valuation allowance.
• Operating loss improved slightly to $(1,230,020) in 2025 from $(1,408,217) in 2024.
• Research, development, and sustaining engineering expenses decreased by 4% to $2,152,843 in 2025, mainly due to reduced payments to outside contractors for SpinDetect development.
• General and administrative expenses rose by 11% to $1,388,160, primarily due to public company and legal expenses related to S-4 filings.
• Interest expense increased substantially to $119,190 in 2025 from $40,145 in 2024, driven by new subordinated debentures.
• Cash and cash equivalents decreased by $497,745, ending 2025 at $746,001.
• The company's merger agreement with Electronic Systems Technology, Inc. (ELST) was terminated in February 2026 after ELST shareholders did not provide the required approval.
• The rental property segment was discontinued effective June 30, 2025, with the company now occupying the entire premises for its operations.
• Development of the SpinDetect microfluidic detection platform is advancing, with beta testing expected to begin in 2026 and a commercial launch later in the year, focusing initially on oral-fluid delta-9-THC detection.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment. While revenue growth and SpinDetect's potential are positive, the significantly increased net loss, declining cash, and failed merger raise substantial concerns about current financial health and execution risk.

Positives

• Total revenues increased by 6% in 2025, driven by new customer acquisitions and expansion within existing accounts.
• Gross profit also increased by 6% in 2025, maintaining a stable gross profit margin on products at 40%.
• Operating loss decreased by $178,197, indicating improved operational efficiency before other income/expenses and taxes.
• The SpinDetect microfluidic detection platform is progressing towards beta testing and commercial launch in 2026, with a unique capability to isolate psychoactive delta-9-THC.
• The company has filed its first Lifeloc-owned utility patent application for improvements to the SpinDetect system.
• Management believes the core breathalyzer business remains fundamentally sound and capable of supporting ongoing operations on a cost-reduced basis.

Negatives

• Net loss significantly widened to $2,470,399 in 2025 from $1,052,948 in 2024, primarily due to a $1,159,199 increase in the deferred tax asset valuation allowance.
• Cash and cash equivalents decreased by $497,745, ending the year with $746,001.
• Interest expense increased by $79,045, reflecting higher debt service costs from new subordinated debentures.
• The proposed merger with Electronic Systems Technology, Inc. (ELST) was terminated due to lack of shareholder approval.
• The R.A.D.A.R. 200 product met with little market acceptance and was withdrawn in 2022, with R.A.D.A.R. 300 development currently on hold.
• Total stockholders' equity decreased significantly from $6,225,877 in 2024 to $4,103,778 in 2025.

Risks

• Global economic conditions, exchange rate fluctuations, and country-by-country economic conditions could negatively impact business.
• Changes in trade policy and tariffs could increase costs and adversely affect sales.
• Geopolitical instability and international conflicts may disrupt operations, supply chain, and financial performance.
• Reliance on a few major customers (18% of product sales from three customers in 2025) poses a risk if orders are not renewed.
• Heavy reliance on the talents of Chief Executive Officer, Dr. Wayne R. Willkomm, whose loss could severely damage the business.
• Inability to attract and retain employees with scientific and technical skills, or labor shortages, could damage the business.
• Growth depends on the timely development, commercialization, and customer acceptance of new and enhanced products like SpinDetect.
• Ongoing investment in new products, services, and technologies is inherently risky and could disrupt ongoing businesses.
• Subject to a high degree of regulatory oversight, and failure to receive necessary DOT or other regulatory approvals could decline revenues.
• Business in the domestic law enforcement area is susceptible to changes in state policies and DUI laws.
• Reliance on state contracts, which are governed by policies beyond control and often lack purchase guarantees.
• Third parties may infringe on patents, leading to significant protection expenses or insufficient resources to protect them.
• Claims of patent infringement by third parties could prohibit the use of technology or lead to costly litigation.
• Failure of third parties from whom key intellectual property is licensed (e.g., Sandia Corporation for SpinDetect) to protect their IP could adversely affect the business.
• Dependence on a few sources for key supplies, particularly fuel cells, poses a risk of supply disruption.
• Exposure to product liability claims, with insurance potentially insufficient to cover all future liabilities.
• Potential liability if business operations harm the environment, or failure to comply with environmental laws.
• Climate change may adversely impact business through increased costs or reduced demand.
• Quarterly financial results vary significantly, which could adversely affect stock price.
• Identification of material weaknesses in internal control over financial reporting may adversely affect financial results.
• May require additional capital in the future, which may not be available or only on unfavorable terms, potentially delaying or discontinuing SpinDetect development.
• Outstanding indebtedness requires ongoing debt service and could limit financial flexibility.
• Competition from larger, well-financed competitors with superior resources.
• Reliance on fuel cell technology that may become outdated or out of favor.
• Natural disasters, public health crises, political crises, and other catastrophic events could damage facilities or impact customer priorities.
• Increasingly common data privacy and cybersecurity regulations impact the use of or market for products, and cybersecurity attacks pose risks.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.
• Shares of common stock lack a significant trading market and may experience volatility.
• Principal stockholder (Vern D. Kornelsen) has significant voting power (77%), potentially taking actions not in the best interests of other stockholders.
• Stockholders should not anticipate receiving cash dividends on stock.
• Future issuance of shares may dilute existing interests.
• Blue Sky considerations limit sales in certain states.
• Compliance with changing regulations of corporate governance and public disclosure results in expense and diversion of management time.

Future Outlook

The company anticipates commercialization of new sensing and measurement products, particularly the SpinDetect platform, which is expected to begin beta testing and commercial launch in 2026. They expect to continue increasing sales in the U.S. and worldwide through expanded distribution and new products. Research and development expenses are expected to continue as SpinDetect nears completion and base products are updated. Management believes cash resources will be sufficient for the next twelve months under the current operating plan, but additional capital may be required if profitability is not regained or SpinDetect commercialization is delayed or more costly than anticipated.

Management Comments

• "We remain committed to growing our breath alcohol testing business."
• "In the future, we anticipate the commercialization of new sensing and measurement products that may allow Lifeloc to successfully expand our business into new growth areas where we do not presently compete or where no satisfactory product solutions exist today."
• "We are optimistic about the results of the work to date and expect market introduction via beta testing beginning in 2026, with a sales-ready device later in 2026."
• "Once this difference [SpinDetect's ability to isolate delta-9-THC] becomes more widely known, Lifeloc believes society will begin to develop a consensus as to what level is unacceptable for driving (similar, for example, to .05 for alcohol)."
• "We believe the installed base of our breathalyzers will increase as the inherent risks associated with drinking while driving or while working in safety sensitive jobs become more widely acknowledged and as our network of distributors and our direct sales force grows."
• "We believe that increased marketing efforts, the introduction of new products and the expansion of our sales network may provide the basis for increased sales and continuing profitable operations."
• "We expect to continue to incur research and development expenses as we near completion of the first phase of SpinDetect and to update our base products."
• "We believe our core product and services business, at current revenue levels, is capable of supporting ongoing operations on a cost-reduced basis."
• "We intend to continue managing costs carefully while advancing SpinDetect toward its anticipated commercial launch later in 2026."
• "We believe that our cash and receivables position, combined with cash generated from ongoing product sales, cost reductions already implemented, and the availability of additional financing if needed, are sufficient to fund our operations and meet our financial obligations for the foreseeable future."

Industry Context

StockSavvy.ai notes that Lifeloc operates in a highly competitive market for portable breath alcohol testing instruments, facing established players like Intoximeters, CMI, and Drägerwerk. The company is also entering the emerging and competitive marijuana breathalyzer market with SpinDetect, where it faces well-funded competitors such as Cannabix Technologies and Hound Labs. The broader industry is seeing a global trend towards tougher alcohol abuse prevention laws, which could drive demand for Lifeloc's core products. The company's expansion into drug detection, particularly with its unique SpinDetect technology, positions it to capitalize on unmet needs in rapid, quantitative drug testing, potentially disrupting traditional lab-based methods.

Comparison to Industry Standards

• SpinDetect's patented capability to isolate psychoactive delta-9-THC from inactive metabolites provides more accurate impairment-relevant results compared to competitive devices like Dräger's Drugtest 5000 and the Sotoxa device, which are unable to make this separation.
• The expected cost of SpinDetect at around $25 per test for local, rapid results is significantly lower than the $100-$300 per test for traditional outside lab analysis, positioning it as a cost-effective alternative.
• The company's fuel-cell based breath alcohol testers are DOT approved, meeting industry standards for evidential breath testing, similar to established competitors.

Management Changes

Corporate Governance

Legal Proceedings

• Not aware of any material pending legal proceedings, other than ordinary routine litigation incidental to the business, as of December 31, 2025 and 2024.

Related Party Transactions

• On July 23, 2024, 210,000 shares of common stock were sold to EDCO Partners LLLP, an accredited investor of which the CFO and Board Chairman, Vern D. Kornelsen, is the managing partner, for $798,000.
• In February 2025, options to purchase 88,500 shares of common stock were assigned by option holders to EDCO Partners LLLP and a third director, then exercised at $3.80 per share for total proceeds of $336,300 to the company.

Stakeholder Impact

• Shareholders experienced significant dilution from recent capital raises and a substantial decrease in total stockholders' equity due to the increased net loss.
• The principal stockholder, Vern D. Kornelsen, maintains significant voting power (approximately 77%), which allows control over the company's direction and policies.
• Employees benefit from a renewed employment agreement for the CEO and continued investment in growth and development, along with comprehensive benefits.
• Customers may benefit from the anticipated commercialization of the SpinDetect platform, offering advanced and more accurate drug testing solutions.
• Creditors face increased exposure due to the issuance of new subordinated debentures, increasing the company's overall indebtedness.

Next Steps

• Continue work on SpinDetect, with beta testing of the oral-fluid analyzer focused on delta-9-THC detection beginning in 2026.
• Commercial launch of the SpinDetect base reader unit, oral fluid collection device, and analysis disk expected later in 2026.
• Subsequent product releases for SpinDetect will include multi-drug panels and utilize samples from blood and breath.
• Expand drug detection offerings based on the SpinDetect technology platform into adjacent markets like public health, food safety, and environmental testing.
• Focus development efforts on products offering the best prospects to increase intermediate and near-term revenues.
• Grow sales of base products and increase gross profits.
• Actively research and engage in the acquisition of resources aligned with near and remote sensing and monitoring products and solutions.
• Continue managing costs carefully while advancing SpinDetect toward its anticipated commercial launch.

Key Dates

Recommendation

The company's significantly increased net loss and declining cash position in 2025 are concerning, exacerbated by the failed merger attempt. However, the losses are explicitly attributed to strategic, deliberate investments in the promising SpinDetect platform, which has unique competitive advantages and is nearing commercial launch. For existing investors, holding the stock to see the outcome of SpinDetect's market introduction in 2026 might be warranted given the potential long-term upside. For new investors, the current financial weakness, high execution risk for SpinDetect, and the illiquid nature of the stock suggest caution, making a 'hold' a more appropriate stance than a 'buy' or 'sell' at this juncture, pending clearer signs of SpinDetect's commercial success and a return to profitability.

Keywords

Breathalyzers, Drug Testing, SpinDetect, Alcohol Detection, Marijuana Testing, Fuel Cell Technology, Law Enforcement, Workplace Testing, SEC Filing, Annual Report, LCTC, Microfluidics, Biometrics, Corporate Governance, Financial Performance